TY - JOUR TI - A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein AU - Kim, Cheolmin AU - Ryu, Dong-Kyun AU - Lee, Jihun AU - Kim, Young-Il AU - Seo, Ji-Min AU - Kim, Yeon-Gil AU - Jeong, Jae-Hee AU - Kim, Minsoo AU - Kim, Jong-In AU - Kim, Pankyeom AU - Bae, Jin Soo AU - Shim, Eun Yeong AU - Lee, Min Seob AU - Kim, Man Su AU - Noh, Hanmi AU - Park, Geun-Soo AU - Park, Jae Sang AU - Son, Dain AU - An, Yongjin AU - Lee, Jeong No AU - Kwon, Ki-Sung AU - Lee, Joo-Yeon AU - Lee, Hansaem AU - Yang, Jeong-Sun AU - Kim, Kyung-Chang AU - Kim, Sung Soon AU - Woo, Hye-Min AU - Kim, Jun-Won AU - Park, Man-Seong AU - Yu, Kwang-Min AU - Kim, Se-Mi AU - Kim, Eun-Ha AU - Park, Su-Jin AU - Jeong, Seong Tae AU - Yu, Chi Ho AU - Song, Youngjo AU - Gu, Se Hun AU - Oh, Hanseul AU - Koo, Bon-Sang AU - Hong, Jung Joo AU - Ryu, Choong-Min AU - Park, Wan Beom AU - Oh, Myoung-don AU - Choi, Young Ki AU - Lee, Soo-Young T2 - Nature Communications AB - Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19. DA - 2021/01/12/ PY - 2021 DO - 10.1038/s41467-020-20602-5 DP - www.nature.com VL - 12 IS - 1 SP - 288 LA - en SN - 2041-1723 UR - https://www.nature.com/articles/s41467-020-20602-5 Y2 - 2021/01/13/00:52:32 ER -